Ex vivo phenotyping and potency monitoring of CD19 CAR T cells
5 Nov 2020The development of cell-mediated immunotherapies has revolutionized cancer research as well as the study of the immune system. One of the most promising types of cell therapy involves the genetic engineering of novel chimeric antigen receptor (CAR) T cells to target cancer cells. To efficiently determine optimal CAR construction, researchers must develop a robust screening protocol to identify the ideal parent T cell populations and evaluate their cell killing potency. In this application note a workflow using a combination of the Agilent xCELLigence RTCA analyzer and Agilent NovoCyte Quanteon flow cytometer to thoroughly evaluate and characterize CAR T cells is described.
Related products
Request Quote for All Products
xCELLigence RTCA HT
Agilent TechnologiesThe Agilent xCELLigence Real-Time Cell Analysis (RTCA) HT instrument uses label-free cellular impedance to continuously monitor cell health, behavior, and function with high accuracy, sensitivity, and reproducibility. Simply plate cells, add treatments, and begin monitoring cell behavior to obtain real-time kinetic data for assay windows that stretch from seconds to days. The HT model can run a 384-well electronic microplate (E-Plate 384), which is ideal for high-throughput screening experiments. Integrate up to 4 instruments controlled by a single control unit for a total of 1,536 wells to meet high throughput sample screening needs. The RTCA HT model can be used as a single instrument on a standard lab bench or integrated into a multi-instrument high-throughput workflow with automated liquid handling. For Research Use Only. Not for use in diagnostic procedures.
